Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 5/20 | 0.41 |
| ▸ | FLT4 | P35916 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583836 | 0.79 | ACLY (0.54) | ADRB1ADRB3MYCALDH1A1L3MBTL1 | |
| SCHEMBL30633692 | 0.79 | MAPK1 (0.42) | ALDH1A1L3MBTL1ACLYMAPK1USP2 | |
| SCHEMBL4584618 | 0.78 | ADRB3 (0.51) | ADRB1ADRB3ALDH1A1 | |
| SCHEMBL4584018 | 0.77 | ADRB3 (0.50) | ADRB1ADRB3FLT1FLT4KDR | |
| SCHEMBL4583570 | 0.76 | ADRB3 (0.51) | ADRB1ADRB3FLT1FLT4KDR | |
| SCHEMBL4585616 | 0.76 | ABCG2 (0.49) | ALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL27668022 | 0.75 | ACLY (0.39) | IRAK4ALDH1A1L3MBTL1ACLYBCL2L1 | |
| SCHEMBL4583885 | 0.75 | ADRB1 (0.42) | ADRB1ADRB3IRAK4MYC | |
| SCHEMBL30633733 | 0.75 | HSP90AB1 (0.40) | ALDH1A1L3MBTL1ACLYMAPK1USP2 | |
| SCHEMBL4584858 | 0.74 | ADRB3 (0.41) | ADRB1ADRB3FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB1 70/4885ADRB3 86/4885IRAK4 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.